Treatment of Acute Pericarditis With Anakinra
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Pain Score
研究概览
简要总结
The goal of this study is to determine the safety and efficacy of anakinra for the treatment of acute pericarditis when initiated within 6 hours of diagnosis and continued for 3 or 7 days.
- to determine the efficacy of anakinra with respect to chest pain resolution
- to determine the safety of anakinra with respect to adverse drug events
详细描述
Acute pericarditis is a clinical syndrome characterized by a profound inflammation of the membrane tissue that surrounds, supports and protects the heart. Acute pericarditis can be caused by a variety of infectious and non-infectious agents, but it most commonly either follows a viral infection of the upper respiratory tract or has no apparent cause.
Acute pericarditis occurs rather abruptly in previously healthy individuals, generally a child or young adult. Most cases of acute pericarditis resolve within a few days with non-steroidal anti-inflammatory drugs. However, patients experience severe chest pain and are at high risk for life-threatening complications involving the pericardium, such as pericardial tamponade. Acute pericarditis is diagnosed in 1 in 20 (5%) ED visits for chest pain.
Anakinra (Kineret) has been shown to treat and cure refractory and recurrent pericarditis. This study is aimed at determining whether anakinra is also effective as first line treatment in acute pericarditis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥12 years in presence of a parent able to provide consent or age >18 years
- •First or recurrent episode of acute pericarditis, defined as the presence of at least 2 of the following:
- •Chest pain (suggestive of pericarditis and not explained by another condition)
- •Pericardial friction rub on physical exam
- •ST-segment elevation and/or PR depression on ECG
- •New or worsening pericardial effusion
- •Pain of moderate-to-severe intensity (pain score ≥6 on a scale of 0-10 where 0 is no pain at all and 10 is the worst pain ever experienced) at time on enrollment
- •Ability to provide written informed consent if 18 years or older or to provide assent in presence of parental consent if 12-17 years of age
排除标准
- •Pericarditis due to known bacterial or fungal infection
- •Pericarditis due to known malignancy
- •Pericarditis after cardiac surgery
- •Tamponade or need for pericardiocentesis for diagnostic/therapeutic purposes
- •Pregnancy or breastfeeding
- •Hypersensitivity to anakinra, latex or products derived from Escherichia coli
- •Chronic pain syndrome or chronic use of analgesic drugs
研究组 & 干预措施
Anakinra
100 mg subcutaneous injection
干预措施: Anakinra (Drug)
Placebo
100 mg NaCl 0.9% subcutaneous injection
干预措施: Placebo (Drug)
结局指标
主要结局
Pain Score
时间窗: Baseline to 6 hours
Change from baseline in visual analog pain score from 0 to 10. For this visual analog pain scale, the patient is asked to rate their pain from 0 to 10. A score of 0 represents "no pain", a score of 5 represents "moderate pain", and 10 represents "worst pain".
次要结局
- Pain Score(Baseline to 24 hours)